StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck cubicin (daptomycin, legacy) — U.S. sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

QuarterlyAnnual
Latest, Q4 2020
10
Period ended Dec 31, 2020
Change on a year earlier
-23.1%
13 in Q4 2019
History
17 quarters
Since Q4 2016
Sources
13
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCubicin (daptomycin, legacy) — U.S. sales ($M) ($M)Year on yearSource
Q4 2020Dec 31, 202010-23.1%Form 10-K (filed 2021-02-25) ↗
Q3 2020Sep 30, 202011-21.4%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 202010-54.5%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 202015-64.3%Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2019Dec 31, 201913-68.3%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2019Sep 30, 201914-74.5%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2019Jun 30, 201922-54.2%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2019Mar 31, 201942-10.6%Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2018Dec 31, 201841+2.5%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2018Sep 30, 201855+34.1%Form 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗
Q2 2018Jun 30, 201848-9.4%Form 8-K (a19-15283_1ex99d1.htm, filed 2019-07-30) ↗
Q1 2018Mar 31, 201847-13.0%Form 8-K (a19-8996_1ex99d1.htm, filed 2019-04-30) ↗
Q4 2017Dec 31, 201740-51.2%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2017Sep 30, 201741–Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗
Q2 2017Jun 30, 201753–Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗
Q1 2017Mar 31, 201754–Form 8-K (a18-12417_1ex99d1.htm, filed 2018-05-01) ↗

Breakdown

What makes up cubicin (daptomycin, legacy) — u.s. sales ($m)

Cite this data

StockData. (2026). Merck Cubicin (daptomycin, legacy) — U.S. sales ($M) ($M), quarterly Q4 2016–Q4 2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_cubicin_us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.